Description
This product is a hot-start DNA polymerase that utilizes two proprietary antibodies for dual blocking. It effectively inhibits both the 5'→3' polymerase activity and the 5'→3' exonuclease activity of Taq DNA polymerase. Upon heating at the pre-denaturation temperature for 30 seconds, the blocking antibodies are completely inactivated, releasing both the DNA polymerase and exonuclease activities.
This dual-blocking feature offers a dual advantage: it not only prevents non-specific amplification caused by mismatches or primer-dimers but also inhibits the degradation of probes that can lead to a decrease in fluorescent signal. This dual protection ensures greater stability of in vitro diagnostic reagents during transportation or when used at room temperature.
Features
- Antibody-mediated hot start: Activated by a brief 95 °C incubation (30–60 s) for precise reaction control.
- High sensitivity & specificity: Reliable target detection with minimal non-specific amplification.
- Inhibitor tolerant: Performs well in the presence of common inhibitors from blood, swabs, and residual prep reagents (e.g., phenol, alcohol).
|
Components No. |
Name |
14325ES76 (1,000 U) |
14325ES80 (10,000 U) |
14325ES92 (25,000 U) |
14325ES93 (100,000 U) |
|
14325 |
Robust Hotstart Taq (20 U/μL) |
50 μL |
500 μL |
1.25 mL |
5 mL |
Components
Storage
This product should be stored at -25~-15℃ for 2 years.
Figure
1. Direct Amplification from Swab Samples
Nasopharyngeal swabs were vortexed in a direct lysis buffer or diluted in TE buffer to prepare templates at equivalent concentrations. Both were tested using the 14325 qPCR master mix and a leading commercial alternative. Results showed that the 14325 formulation exhibits superior inhibitor tolerance, enabling reliable direct amplification from swab samples without purification.
Figure 1. Comparison of direct swab amplification performance: 14325 vs. commercial reagents.
2. Direct Amplification from Plasma Samples
Clinical plasma samples were diluted in either plasma itself or TE buffer to match template concentrations. When tested with the 14325 qPCR mix and a commercial reagent, the 14325 system demonstrated significantly better resistance to inhibitors—supporting direct amplification with up to 30% final plasma concentration.
Figure 2. Comparison of direct plasma amplification performance: 14325 vs. commercial reagent.
Documents:
Safety Data Sheet
Manuals
14325_Manual_Ver.EN20260304.pdf
Paiement et sécurité
Vos informations de paiement sont traitées en toute sécurité. Nous ne stockons pas les détails de la carte de crédit ni accès aux informations de votre carte de crédit.
Vous pouvez aussi aimer
Enquête
FAQ
Le produit est destiné à des fins de recherche uniquement et n'est pas destiné à un usage thérapeutique ou diagnostique chez l'homme ou l'animal. Les produits et le contenu sont protégés par des brevets, des marques déposées et des droits d'auteur appartenant à Yeasen Biotechnology. Les symboles de marque indiquent le pays d'origine, pas nécessairement l'enregistrement dans toutes les régions.
Certaines applications peuvent nécessiter des droits de propriété intellectuelle tiers supplémentaires.
Yeasen se consacre à la science éthique, estimant que nos recherches doivent répondre à des questions cruciales tout en garantissant la sécurité et les normes éthiques.